26. January 2018

2017 was a landmark year for the pharmaceutical industries in the US and Europe, with a sharp increase in the number of new molecular entities (NMEs) being approved in both the geographies. The US Food and Drug Administration (USFDA) approved 46 NMEs in 2017, a strong bounce back from only 22 NMEs approved in 2016.

15. November 2017

Poor water-solubility remains a typical property of drug candidates in pharmaceutical development pipelines today. Various processes have been developed to increase the solubility, dissolution rate, and bioavailability of these active ingredients belonging to biopharmaceutical classification system (BCS) II and IV classifications. Since the early 2000s, nanocrystal delivery and amorphous solid dispersions are more established techniques to overcome the limitations of poorly-water soluble drugs..